As AI-assisted coding accelerates software development, security teams are facing a growing challenge managing expanding open ...

Here’s what happens when email apnea and associated anxiety causes shallow breathing: Marsh said the body drops into a ...

Americans love science and revere innovation, almost as a rule, and politicians of every stripe have spent the better part of a century promoting and protecting both. However imperfect the resulting ...

US Supreme Court justices (SCOTUS) ruled 6 to 3 in favor of striking down President Trump's sweeping trade tariffs on Friday, finding these policies were not authorized under IEEPA (International ...

Cisco’s new AI Technical Practitioner (AITECH) certification is focused on practical, role-oriented skills for integrating generative AI, automation, and ethics into modern infrastructure management.

Abcuro, Inc., today announced topline results from the Phase 2/3 MUSCLE clinical study of ulviprubart (ABC008), an investigational monoclonal antibody in development for the treatment of patients with ...

Senior royals have faced scandal, public criticism, and civil litigation. But being formally arrested and questioned on suspicion of a criminal offence marks a striking moment ...

The Dell Pro 14 Premium PA14250 is one of those laptops that makes sense the moment you stop judging it as “just another 14-inch Windows machine” and start looking at what its ...

Our team of savvy editors independently handpicks all recommendations. If you make a purchase through our links, we may earn a commission. Deals and coupons were accurate at the time of publication ...

OpenAI wants to retire the leading AI coding benchmark—and the reasons reveal a deeper problem with how the whole industry measures itself.

As the population ages, China will face an ever-increasing burden from CS. Strategies targeting elder population and high-risk groups should be prioritized in the establishment of management related ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2025.